The answer to Genetic Blindness starts with a clear vision
The focus is on investigational genetic therapies to save and restore the vision of patients with rare inherited retinal conditions.
The focus is on investigational genetic therapies to save and restore the vision of patients with rare inherited retinal conditions.
Your patient may qualify to participate in the Vista clinical trial, a phase 2/3 study evaluating an investigational gene therapy for the treatment of retinitis pigmentosa. Patients must meet the following criteria:
Beacon Therapeutics is currently pre-screening male patients between the ages of 12-50 (inclusive) diagnosed with X-linked retinitis pigmentosa (XLRP) for the Vista trial.
learn moreGenetic testing is critical to the diagnosis of patients with Inherited Retinal Disease. Learn more about the free genetic testing that may be available for your patients.
learn moreGene therapy targets the exact cause of a disease and aims to treat the disease through a one-time administration.
learn moreBeacon Therapeutics is an ophthalmic gene therapy company founded in 2023 to save and restore the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
We have an established scientific foundation that combines a late-stage development candidate to treat X-linked retinitis pigmentosa (XLRP) with two preclinical programs, one targeting dry age-related macular degeneration (dAMD) and another targeting cone-rod dystrophy (CRD).
Learn more at beacontx.comTo enter the site, please indicate that you are a Healthcare Professional